Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACV2 | ISIN: ES0167733015 | Ticker-Symbol: ORN
Tradegate
25.06.25 | 12:52
2,645 Euro
-1,67 % -0,045
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORYZON GENOMICS SA Chart 1 Jahr
5-Tage-Chart
ORYZON GENOMICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,6502,72528.06.
2,6552,72027.06.

Aktuelle News zur ORYZON GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Ordinary General Shareholders' Meeting1
MiOryzon Genomics, S.A.: ORYZON to Host Virtual KOL Event on July 9, 20251
DiOryzon Genomics - A step closer to a new treatment paradigm in BPD191Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat, in borderline personality disorder (BPD), marking...
► Artikel lesen
MoOryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients90PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified...
► Artikel lesen
MoORYZON GENOMICS, S.A.: ORYZON announces the submission to the FDA of the clinical trial protocol for its Phase III PORTICO-2 trial of vafidemstat in Borderline Personality Disorder patients1
17.06.Oryzon Genomics, S.A.: ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-293
27.05.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in May-June1
26.05.ORYZON GENOMICS, S.A.: Call of the Ordinary General Shareholders' Meeting of Oryzon Genomics, S.A.2
ORYZON GENOMICS Aktie jetzt für 0€ handeln
19.05.Oryzon Genomics - Preparations in place for an active 2025287Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple early-stage studies. Operating performance was unsurprising...
► Artikel lesen
12.05.Oryzon Genomics S.A. GAAP EPS of -$0.032
08.05.Oryzon Genomics - €13.3m grant improves operating headroom268Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common European Interest (IPCEI) framework, launched in May 2024....
► Artikel lesen
08.05.Oryzon Genomics, S.A.: ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)96Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism...
► Artikel lesen
24.04.Oryzon Genomics - Capital raise to support long-term strategy318Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other corporate initiatives, offering the potential to extend its...
► Artikel lesen
21.04.Oryzon Genomics, S.A.: ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat156MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics...
► Artikel lesen
15.04.Oryzon Genomics - First patient dosed in iadademstat + ICI SCLC trial308Oryzon Genomics has announced that the first patient has been dosed in iadademstat's Phase I/II trial, sponsored by the National Cancer Institute, (NCI) in extensive-stage small cell lung cancer (SCLC)....
► Artikel lesen
14.03.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April553BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...
► Artikel lesen
05.03.Oryzon Genomics, S.A.: Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat1
05.03.Oryzon (BME: ORY) publishes results of vafidemstat in PMS360Oryzon Genomics has announced the publication of a study in Frontiers in Psychiatry, which explores the potential of vafidemstat in Phelan-McDermid Syndrome (PMS). PMS is a form of autism whereby agitation...
► Artikel lesen
04.03.Oryzon Genomics - All steady heading into 2025377Oryzon has reported its FY24 results, reflecting steady progress across its pipeline. Oryzon's highest value-driving programme remains vafidemstat in borderline personality disorder (BPD), which, following...
► Artikel lesen
28.02.ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Extraordinary General Shareholders' Meeting2
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1